XML 25 R41.htm IDEA: XBRL DOCUMENT v3.20.2
Label Element Value
AllianzGI Health Sciences Fund  
Risk/Return: rr_RiskReturnAbstract  
Risk/Return [Heading] rr_RiskReturnHeading AllianzGI Health Sciences Fund
Objective [Heading] rr_ObjectiveHeading Investment Objective
Objective, Primary [Text Block] rr_ObjectivePrimaryTextBlock
The Fund seeks long-term capital appreciation.
Expense [Heading] rr_ExpenseHeading Fees and Expenses of the Fund
Expense Narrative [Text Block] rr_ExpenseNarrativeTextBlock
The tables below describe the fees and expenses that you may pay if you buy and hold shares of the Fund. In addition to the fees and expenses described below, you may also be required to pay brokerage commissions on purchases and sales of Class P shares of the Fund. You may qualify for sales charge discounts if you and your family invest, or agree to invest in the future, at least $50,000 in Class A shares of eligible funds that are part of the family of mutual funds sponsored by Allianz. More information about these and other discounts is available in the “Classes of Shares” section beginning on page 97 of the Fund’s prospectus or from your financial advisor. In addition, if you purchase shares through a specific intermediary, you may be subject to different sales charges including reductions in or waivers of such charges. More information about these intermediary-specific sales charge variations is available in Appendix A to the Fund’s prospectus (“Intermediary Sales Charge Discounts and Waivers”).
Shareholder Fees Caption [Text] rr_ShareholderFeesCaption Shareholder Fees (fees paid directly from your investment)
Operating Expenses Caption [Text] rr_OperatingExpensesCaption Annual Fund Operating Expenses (expenses that you pay each year as a percentage of the value of your investment)
Portfolio Turnover [Heading] rr_PortfolioTurnoverHeading Portfolio Turnover.
Portfolio Turnover [Text Block] rr_PortfolioTurnoverTextBlock

The Fund pays transaction costs, such as commissions, when it buys and sells securities (or “turns over” its portfolio). The Fund’s portfolio turnover rate for the fiscal year ended June 30, 2020 was 91% of the average value of its portfolio. High levels of portfolio turnover may indicate higher transaction costs and may result in higher taxes for you if your Fund shares are held in a taxable account. These costs, which are not reflected in Total Annual Fund Operating Expenses or in the Examples above, can adversely affect the Fund’s investment performance.

Portfolio Turnover, Rate rr_PortfolioTurnoverRate 91.00%
Expense Example [Heading] rr_ExpenseExampleHeading Examples.
Expense Example Narrative [Text Block] rr_ExpenseExampleNarrativeTextBlock

The Examples are intended to help you compare the cost of investing in shares of the Fund with the costs of investing in other mutual funds. The Examples assume that you invest $10,000 in the noted class of shares for the time periods indicated, your investment has a 5% return each year, and the Fund’s operating expenses remain the same. Although your actual costs may be higher or lower, the Examples show what your costs would be based on these assumptions whether you redeem your shares at the end of each period or do not redeem your shares.

Expense Example by, Year, Caption [Text] rr_ExpenseExampleByYearCaption Example: Assuming you redeem your shares at the end of each period
Expense Example, No Redemption, By Year, Caption [Text] rr_ExpenseExampleNoRedemptionByYearCaption Example: Assuming you do not redeem your shares
Strategy [Heading] rr_StrategyHeading Principal Investment Strategies
Strategy Narrative [Text Block] rr_StrategyNarrativeTextBlock

The Fund seeks to achieve its objective by normally investing at least 80% of its net assets (plus borrowings made for investment purposes) in health sciences-related companies. The Fund considers health sciences-related companies to include companies that design, manufacture or sell products or services used for or in connection with healthcare, medicine or life sciences. The Fund will invest primarily in common stocks and other equity securities. Although the Fund may invest in companies of any market capitalization, the Fund does not currently intend to invest more than 15% of its assets in companies with market capitalizations below $1 billion. The Fund may invest in U.S. and non-U.S. companies, and currently expects the majority of its non-U.S. investments will normally be in Asia and Western Europe. The Fund may invest up to 15% of its assets in emerging market securities (but no more than 10% in any one emerging market country). In analyzing specific companies for possible investment, the portfolio managers ordinarily look for the following characteristics: higher than average growth and strong potential for capital appreciation; substantial capacity for growth in revenue through either an expanding market or market share; a strong balance sheet; superior management; strong commitment to research and product development; and differentiated or superior products and services or a steady stream of new products and services. In addition to common stocks and other equity securities (such as preferred stocks, convertible securities and warrants), the Fund may invest in securities issued in initial public offerings (IPOs), and may utilize foreign currency exchange contracts, options, stock index futures contracts, short sales and other derivative instruments. Although the Fund did not invest significantly in derivative instruments as of the most recent fiscal year end, it may do so at any time. While the Fund may invest in derivatives of any kind, it expects to purchase put and call options on securities for hedging, risk management or other purposes.
Risk [Heading] rr_RiskHeading Principal Risks
Risk Narrative [Text Block] rr_RiskNarrativeTextBlock
The principal risks of investing in the Fund, which could adversely affect its net asset value, yield and total return, are (in alphabetical order after the first five risks):

Market Risk:  The Fund will be affected by factors influencing the U.S. or global economies and securities markets or relevant industries or sectors within them.


Issuer Risk:  The Fund will be affected by factors specific to the issuers of securities and other instruments in which the Fund invests, including actual or perceived changes in the financial condition or business prospects of such issuers.


Equity Securities Risk:  Equity securities may react more strongly to changes in an issuer’s financial condition or prospects than other securities of the same issuer.


Focused Investment Risk (Health Sciences-Related Risk):  To the extent the Fund focuses its investments on a limited number of issuers, sectors, industries or geographic regions, it may be subject to increased risk and volatility. Risks affecting companies in the health sciences sector include new government regulations or changes to existing regulations, changes in government subsidy and reimbursement levels and product or service approvals, rapid obsolescence of products or services, dramatic fluctuations of economic prospects and healthcare-related liability issues.


Smaller Company Risk:  Securities issued by smaller companies may be more volatile and present increased liquidity risk relative to securities issued by larger companies.


Credit and Counterparty Risk:  An issuer or counterparty may default on obligations.


Currency Risk:  The values of non-U.S. securities may fluctuate with currency exchange rates and exposure to non-U.S. currencies may subject the Fund to the risk that those currencies will decline in value relative to the U.S. dollar.


Derivatives Risk:  Derivative instruments are complex, have different characteristics than their underlying assets and are subject to additional risks, including leverage, liquidity and valuation.


Emerging Markets Risk:  Non-U.S. investment risk may be particularly high to the extent that the Fund invests in emerging market securities. These securities may present market, credit, currency, liquidity, legal, political, technical and other risks different from, or greater than, the risks of investing in developed countries.


IPO Risk:  Securities purchased in initial public offerings have no trading history, limited issuer information and increased volatility.


Leveraging Risk:  Instruments and transactions that constitute leverage magnify gains or losses and increase volatility.


Liquidity Risk:  To the extent the Fund invests in less liquid securities or the level of liquidity in a particular market is constrained, the lack of an active market for investments may cause delay in disposition or force a sale below fair value.


Management Risk:  The Fund will be affected by the allocation determinations, investment decisions and techniques of the Fund’s management.


Non-U.S. Investment Risk:  Non-U.S. securities markets and issuers may be more volatile, smaller, less liquid, less transparent and subject to less oversight, particularly in emerging markets.


Short Selling Risk:  Short selling enhances leveraging risk and involves counterparty risk and the risk of unlimited loss.


Turnover Risk:  High levels of portfolio turnover increase transaction costs and taxes and may lower investment performance.


Please see “Summary of Principal Risks” in the Fund’s prospectus for a more detailed description of the Fund’s risks. It is possible to lose money on an investment in the Fund. An investment in the Fund is not a deposit of a bank and is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency.

Risk Lose Money [Text] rr_RiskLoseMoney It is possible to lose money on an investment in the Fund.
RIsk Not Insured [Text] rr_RiskNotInsured An investment in the Fund is not a deposit of a bank and is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency.
Bar Chart and Performance Table [Heading] rr_BarChartAndPerformanceTableHeading Performance Information
Performance Narrative [Text Block] rr_PerformanceNarrativeTextBlock
The performance information below provides some indication of the risks of investing in the Fund by showing changes in its total return from year to year and by comparing the Fund’s average annual total returns with those of a sector-specific broad-based market index and a performance average of similar mutual funds. The bar chart and the information to its right show performance of the Fund’s Class A shares, but do not reflect the impact of sales charges (loads). If they did, returns would be lower than those shown. Other share classes would have different performance due to the different expenses they bear. Performance in the Average Annual Total Returns table reflects the impact of sales charges. For periods prior to the inception date of a share class, performance information shown for such class may be based on the performance of an older class of shares that dates back to the Fund’s inception, as adjusted to reflect fees and expenses paid by the newer class. Similarly, for periods prior to a reorganization of the Fund, in which a predecessor fund was merged into the Fund, the performance information is based on the performance of the predecessor fund, adjusted to reflect fees and expenses paid by the particular share class of the Fund. These adjustments generally result in estimated performance results that are different from the actual results of the predecessor class and/or the predecessor fund, as the case may be, due to differing levels of fees and expenses paid. Details regarding the calculation of the Fund’s class-by-class performance, including a discussion of any performance adjustments, are provided under “Additional Performance Information” in the Fund’s prospectus and SAI. Past performance, before and after taxes, is not necessarily predictive of future performance. Visit us.allianzgi.com for more current performance information.
Performance Information Illustrates Variability of Returns [Text] rr_PerformanceInformationIllustratesVariabilityOfReturns The performance information below provides some indication of the risks of investing in the Fund by showing changes in its total return from year to year and by comparing the Fund’s average annual total returns with those of a sector-specific broad-based market index and a performance average of similar mutual funds.
Performance Availability Website Address [Text] rr_PerformanceAvailabilityWebSiteAddress us.allianzgi.com
Performance Past Does Not Indicate Future [Text] rr_PerformancePastDoesNotIndicateFuture Past performance, before and after taxes, is not necessarily predictive of future performance.
Bar Chart [Heading] rr_BarChartHeading Calendar Year Total Returns — Class A
Bar Chart Does Not Reflect Sales Loads [Text] rr_BarChartDoesNotReflectSalesLoads The bar chart and the information to its right show performance of the Fund’s Class A shares, but do not reflect the impact of sales charges (loads).
Bar Chart Closing [Text Block] rr_BarChartClosingTextBlock
More Recent Return Information

 

1/1/20–6/30/20     1.36%  
Highest and Lowest Quarter Returns

 

(for periods shown in the bar chart)

 

Highest 10/01/2019–12/31/2019     16.46%  
Lowest 07/01/2011–09/30/2011     -15.50%  
Year to Date Return, Label rr_YearToDateReturnLabel More Recent Return Information
Bar Chart, Year to Date Return, Date rr_BarChartYearToDateReturnDate Jun. 30, 2020
Bar Chart, Year to Date Return rr_BarChartYearToDateReturn 1.36%
Highest Quarterly Return, Label rr_HighestQuarterlyReturnLabel Highest
Highest Quarterly Return, Date rr_BarChartHighestQuarterlyReturnDate Dec. 31, 2019
Highest Quarterly Return rr_BarChartHighestQuarterlyReturn 16.46%
Lowest Quarterly Return, Label rr_LowestQuarterlyReturnLabel Lowest
Lowest Quarterly Return, Date rr_BarChartLowestQuarterlyReturnDate Sep. 30, 2011
Lowest Quarterly Return rr_BarChartLowestQuarterlyReturn (15.50%)
Performance Table Does Reflect Sales Loads rr_PerformanceTableDoesReflectSalesLoads Performance in the Average Annual Total Returns table reflects the impact of sales charges.
Index No Deduction for Fees, Expenses, Taxes [Text] rr_IndexNoDeductionForFeesExpensesTaxes (returns reflect no deduction for fees or expenses but are net of dividend tax withholding)
Performance Table Uses Highest Federal Rate rr_PerformanceTableUsesHighestFederalRate After-tax returns are estimated using the highest historical individual federal marginal income tax rates and do not reflect the impact of state and local taxes.
Performance Table Not Relevant to Tax Deferred rr_PerformanceTableNotRelevantToTaxDeferred Actual after-tax returns depend on an investor’s tax situation and may differ from those shown. After-tax returns are not relevant to investors who hold Fund shares through tax-advantaged arrangements such as 401(k) plans or individual retirement accounts.
Performance Table One Class of after Tax Shown [Text] rr_PerformanceTableOneClassOfAfterTaxShown After-tax returns are for Class A shares only. After-tax returns for other share classes will vary.
Performance Table Explanation after Tax Higher rr_PerformanceTableExplanationAfterTaxHigher In some cases the return after taxes may exceed the return before taxes due to an assumed tax benefit from any losses on a sale of Fund shares at the end of the measurement period.
Performance Table Closing [Text Block] rr_PerformanceTableClosingTextBlock

After-tax returns are estimated using the highest historical individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on an investor’s tax situation and may differ from those shown. After-tax returns are not relevant to investors who hold Fund shares through tax-advantaged arrangements such as 401(k) plans or individual retirement accounts. In some cases the return after taxes may exceed the return before taxes due to an assumed tax benefit from any losses on a sale of Fund shares at the end of the measurement period. After-tax returns are for Class A shares only. After-tax returns for other share classes will vary.

Average Annual Return, Caption rr_AverageAnnualReturnCaption Average Annual Total Returns (for periods ended 12/31/19)
AllianzGI Health Sciences Fund | MSCI World Health Care Index (returns reflect no deduction for fees or expenses but are net of dividend tax withholding)  
Risk/Return: rr_RiskReturnAbstract  
Average Annual Returns, 1 Year rr_AverageAnnualReturnYear01 23.24%
Average Annual Returns, 5 Years rr_AverageAnnualReturnYear05 8.50%
Average Annual Returns, 10 Years rr_AverageAnnualReturnYear10 12.29%
Average Annual Returns, Since Inception rr_AverageAnnualReturnSinceInception 8.91%
Average Annual Returns, Inception Date rr_AverageAnnualReturnInceptionDate Dec. 31, 1996
AllianzGI Health Sciences Fund | Lipper Health/Biotechnology Funds Average  
Risk/Return: rr_RiskReturnAbstract  
Average Annual Returns, 1 Year rr_AverageAnnualReturnYear01 26.22%
Average Annual Returns, 5 Years rr_AverageAnnualReturnYear05 8.72%
Average Annual Returns, 10 Years rr_AverageAnnualReturnYear10 15.22%
Average Annual Returns, Since Inception rr_AverageAnnualReturnSinceInception 10.94%
Average Annual Returns, Inception Date rr_AverageAnnualReturnInceptionDate Dec. 31, 1996
AllianzGI Health Sciences Fund | A  
Risk/Return: rr_RiskReturnAbstract  
Maximum Sales Charge (Load) Imposed on Purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice 5.50%
Maximum Contingent Deferred Sales Charge (CDSC) (Load) (as a percentage of the lower of original purchase price or NAV) rr_MaximumDeferredSalesChargeOverOther 1.00% [1]
Management Fees rr_ManagementFeesOverAssets 1.20%
Distribution and/or Service (12b-1) Fees rr_DistributionAndService12b1FeesOverAssets 0.25%
Other Expenses rr_OtherExpensesOverAssets 0.02%
Total Annual Fund Operating Expenses rr_ExpensesOverAssets 1.47%
Expenses Deferred Charges [Text Block] rr_ExpensesDeferredChargesTextBlock For Class A shares, the CDSC is imposed only in certain circumstances where shares are purchased without a front-end sales charge at the time of purchase.
Expense Breakpoint Discounts [Text] rr_ExpenseBreakpointDiscounts You may qualify for sales charge discounts if you and your family invest, or agree to invest in the future, at least $50,000 in Class A shares of eligible funds that are part of the family of mutual funds sponsored by Allianz.
Expense Breakpoint, Minimum Investment Required [Amount] rr_ExpenseBreakpointMinimumInvestmentRequiredAmount $ 50,000
Expense Example, with Redemption, 1 Year rr_ExpenseExampleYear01 691
Expense Example, with Redemption, 3 Years rr_ExpenseExampleYear03 989
Expense Example, with Redemption, 5 Years rr_ExpenseExampleYear05 1,309
Expense Example, with Redemption, 10 Years rr_ExpenseExampleYear10 2,211
Expense Example, No Redemption, 1 Year rr_ExpenseExampleNoRedemptionYear01 691
Expense Example, No Redemption, 3 Years rr_ExpenseExampleNoRedemptionYear03 989
Expense Example, No Redemption, 5 Years rr_ExpenseExampleNoRedemptionYear05 1,309
Expense Example, No Redemption, 10 Years rr_ExpenseExampleNoRedemptionYear10 $ 2,211
Annual Return 2010 rr_AnnualReturn2010 10.37%
Annual Return 2011 rr_AnnualReturn2011 4.92%
Annual Return 2012 rr_AnnualReturn2012 18.44%
Annual Return 2013 rr_AnnualReturn2013 34.24%
Annual Return 2014 rr_AnnualReturn2014 25.18%
Annual Return 2015 rr_AnnualReturn2015 11.65%
Annual Return 2016 rr_AnnualReturn2016 (7.99%)
Annual Return 2017 rr_AnnualReturn2017 17.32%
Annual Return 2018 rr_AnnualReturn2018 4.67%
Annual Return 2019 rr_AnnualReturn2019 26.64%
Average Annual Returns, 1 Year rr_AverageAnnualReturnYear01 19.68%
Average Annual Returns, 5 Years rr_AverageAnnualReturnYear05 8.59%
Average Annual Returns, 10 Years rr_AverageAnnualReturnYear10 13.28%
Average Annual Returns, Since Inception rr_AverageAnnualReturnSinceInception 11.63%
Average Annual Returns, Inception Date rr_AverageAnnualReturnInceptionDate Dec. 31, 1996
AllianzGI Health Sciences Fund | A | After Taxes on Distributions  
Risk/Return: rr_RiskReturnAbstract  
Average Annual Returns, 1 Year rr_AverageAnnualReturnYear01 17.48%
Average Annual Returns, 5 Years rr_AverageAnnualReturnYear05 6.14%
Average Annual Returns, 10 Years rr_AverageAnnualReturnYear10 10.57%
Average Annual Returns, Since Inception rr_AverageAnnualReturnSinceInception 9.82%
AllianzGI Health Sciences Fund | A | After Taxes on Distributions and Sale of Fund Shares  
Risk/Return: rr_RiskReturnAbstract  
Average Annual Returns, 1 Year rr_AverageAnnualReturnYear01 12.60%
Average Annual Returns, 5 Years rr_AverageAnnualReturnYear05 6.03%
Average Annual Returns, 10 Years rr_AverageAnnualReturnYear10 10.04%
Average Annual Returns, Since Inception rr_AverageAnnualReturnSinceInception 9.35%
AllianzGI Health Sciences Fund | C  
Risk/Return: rr_RiskReturnAbstract  
Maximum Sales Charge (Load) Imposed on Purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice none
Maximum Contingent Deferred Sales Charge (CDSC) (Load) (as a percentage of the lower of original purchase price or NAV) rr_MaximumDeferredSalesChargeOverOther 1.00% [1]
Management Fees rr_ManagementFeesOverAssets 1.20%
Distribution and/or Service (12b-1) Fees rr_DistributionAndService12b1FeesOverAssets 1.00%
Other Expenses rr_OtherExpensesOverAssets 0.02%
Total Annual Fund Operating Expenses rr_ExpensesOverAssets 2.22%
Expenses Deferred Charges [Text Block] rr_ExpensesDeferredChargesTextBlock For Class C shares, the CDSC is imposed only on shares redeemed in the first year.
Expense Example, with Redemption, 1 Year rr_ExpenseExampleYear01 $ 325
Expense Example, with Redemption, 3 Years rr_ExpenseExampleYear03 694
Expense Example, with Redemption, 5 Years rr_ExpenseExampleYear05 1,190
Expense Example, with Redemption, 10 Years rr_ExpenseExampleYear10 2,554
Expense Example, No Redemption, 1 Year rr_ExpenseExampleNoRedemptionYear01 225
Expense Example, No Redemption, 3 Years rr_ExpenseExampleNoRedemptionYear03 694
Expense Example, No Redemption, 5 Years rr_ExpenseExampleNoRedemptionYear05 1,190
Expense Example, No Redemption, 10 Years rr_ExpenseExampleNoRedemptionYear10 $ 2,554
Average Annual Returns, 1 Year rr_AverageAnnualReturnYear01 24.71%
Average Annual Returns, 5 Years rr_AverageAnnualReturnYear05 9.01%
Average Annual Returns, 10 Years rr_AverageAnnualReturnYear10 13.08%
Average Annual Returns, Since Inception rr_AverageAnnualReturnSinceInception 11.07%
Average Annual Returns, Inception Date rr_AverageAnnualReturnInceptionDate Dec. 31, 1996
AllianzGI Health Sciences Fund | Institutional Class  
Risk/Return: rr_RiskReturnAbstract  
Maximum Sales Charge (Load) Imposed on Purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice none
Maximum Contingent Deferred Sales Charge (CDSC) (Load) (as a percentage of the lower of original purchase price or NAV) rr_MaximumDeferredSalesChargeOverOther none [1]
Management Fees rr_ManagementFeesOverAssets 1.10%
Distribution and/or Service (12b-1) Fees rr_DistributionAndService12b1FeesOverAssets none
Other Expenses rr_OtherExpensesOverAssets 0.02%
Total Annual Fund Operating Expenses rr_ExpensesOverAssets 1.12%
Expense Example, with Redemption, 1 Year rr_ExpenseExampleYear01 $ 114
Expense Example, with Redemption, 3 Years rr_ExpenseExampleYear03 356
Expense Example, with Redemption, 5 Years rr_ExpenseExampleYear05 617
Expense Example, with Redemption, 10 Years rr_ExpenseExampleYear10 1,363
Expense Example, No Redemption, 1 Year rr_ExpenseExampleNoRedemptionYear01 114
Expense Example, No Redemption, 3 Years rr_ExpenseExampleNoRedemptionYear03 356
Expense Example, No Redemption, 5 Years rr_ExpenseExampleNoRedemptionYear05 617
Expense Example, No Redemption, 10 Years rr_ExpenseExampleNoRedemptionYear10 $ 1,363
Average Annual Returns, 1 Year rr_AverageAnnualReturnYear01 27.08%
Average Annual Returns, 5 Years rr_AverageAnnualReturnYear05 10.21%
Average Annual Returns, 10 Years rr_AverageAnnualReturnYear10 14.32%
Average Annual Returns, Since Inception rr_AverageAnnualReturnSinceInception 12.32%
Average Annual Returns, Inception Date rr_AverageAnnualReturnInceptionDate Dec. 31, 1996
AllianzGI Health Sciences Fund | R6  
Risk/Return: rr_RiskReturnAbstract  
Maximum Sales Charge (Load) Imposed on Purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice none
Maximum Contingent Deferred Sales Charge (CDSC) (Load) (as a percentage of the lower of original purchase price or NAV) rr_MaximumDeferredSalesChargeOverOther none [1]
Management Fees rr_ManagementFeesOverAssets 1.05%
Distribution and/or Service (12b-1) Fees rr_DistributionAndService12b1FeesOverAssets none
Other Expenses rr_OtherExpensesOverAssets 0.02%
Total Annual Fund Operating Expenses rr_ExpensesOverAssets 1.07%
Expense Example, with Redemption, 1 Year rr_ExpenseExampleYear01 $ 109
Expense Example, with Redemption, 3 Years rr_ExpenseExampleYear03 340
Expense Example, with Redemption, 5 Years rr_ExpenseExampleYear05 590
Expense Example, with Redemption, 10 Years rr_ExpenseExampleYear10 1,306
Expense Example, No Redemption, 1 Year rr_ExpenseExampleNoRedemptionYear01 109
Expense Example, No Redemption, 3 Years rr_ExpenseExampleNoRedemptionYear03 340
Expense Example, No Redemption, 5 Years rr_ExpenseExampleNoRedemptionYear05 590
Expense Example, No Redemption, 10 Years rr_ExpenseExampleNoRedemptionYear10 $ 1,306
Average Annual Returns, 1 Year rr_AverageAnnualReturnYear01 27.15%
Average Annual Returns, 5 Years rr_AverageAnnualReturnYear05 10.26%
Average Annual Returns, 10 Years rr_AverageAnnualReturnYear10 14.38%
Average Annual Returns, Since Inception rr_AverageAnnualReturnSinceInception 12.35%
Average Annual Returns, Inception Date rr_AverageAnnualReturnInceptionDate Dec. 31, 1996
AllianzGI Health Sciences Fund | P  
Risk/Return: rr_RiskReturnAbstract  
Maximum Sales Charge (Load) Imposed on Purchases (as a percentage of offering price) rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice none
Maximum Contingent Deferred Sales Charge (CDSC) (Load) (as a percentage of the lower of original purchase price or NAV) rr_MaximumDeferredSalesChargeOverOther none [1]
Management Fees rr_ManagementFeesOverAssets 1.20%
Distribution and/or Service (12b-1) Fees rr_DistributionAndService12b1FeesOverAssets none
Other Expenses rr_OtherExpensesOverAssets 0.02%
Total Annual Fund Operating Expenses rr_ExpensesOverAssets 1.22%
Expense Example, with Redemption, 1 Year rr_ExpenseExampleYear01 $ 124
Expense Example, with Redemption, 3 Years rr_ExpenseExampleYear03 387
Expense Example, with Redemption, 5 Years rr_ExpenseExampleYear05 670
Expense Example, with Redemption, 10 Years rr_ExpenseExampleYear10 1,477
Expense Example, No Redemption, 1 Year rr_ExpenseExampleNoRedemptionYear01 124
Expense Example, No Redemption, 3 Years rr_ExpenseExampleNoRedemptionYear03 387
Expense Example, No Redemption, 5 Years rr_ExpenseExampleNoRedemptionYear05 670
Expense Example, No Redemption, 10 Years rr_ExpenseExampleNoRedemptionYear10 $ 1,477
Average Annual Returns, 1 Year rr_AverageAnnualReturnYear01 26.95%
Average Annual Returns, 5 Years rr_AverageAnnualReturnYear05 10.10%
Average Annual Returns, 10 Years rr_AverageAnnualReturnYear10 14.21%
Average Annual Returns, Since Inception rr_AverageAnnualReturnSinceInception 12.18%
Average Annual Returns, Inception Date rr_AverageAnnualReturnInceptionDate Dec. 31, 1996
[1] For Class A shares, the CDSC is imposed only in certain circumstances where shares are purchased without a front-end sales charge at the time of purchase. For Class C shares, the CDSC is imposed only on shares redeemed in the first year.